Case | Age (years) | Gender | Primary | Regimen | Cycle of onset | Day of onset | 5-FU dosing | DPD testing | Naranjo score [9] | Fluoropyrimidine rechallenge (if any) | Follow-up (months) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 22 | Female | Rectum | m-FOLFOX6 | 1 | 2 | Bolus: 400 mg/m2 D1 Infusion: 2400 mg/m2 over 48 h | Mutation in exon 2, 13 and 18 (heterozygous) | 7 | Capecitabine | 25 |
2 | 30 | Male | Rectum | 5FU/LV | 1 | 4 | Bolus: 400 mg/m2 D1 Infusion: 2400 mg/m2 over 48 h | Wild | 6 | Capecitabine | 23 |
3 | 34 | Male | Rectum | 5FU/LV | 3 | 3 | Bolus: 400 mg/m2 D1 Infusion: 2400 mg/m2 over 48 h | Wild | 6 | None | 8 |
4 | 45 | Female | Stomach | FLOT | 1 | 2 | Infusion:2600 mg/m2 over 24 h | Not done | 6 | Capecitabine | 12 |
5 | 60 | Male | Rectum | FOLFIRINOX | 2 | 3 | Bolus: not given Infusion: 2400 mg/m2 over 48 h | Not done | 6 | Capecitabine | 4 |